FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	ONB APPROVAL									
l	OMB Number:	3235-0287								
l	Estimated average burde	en								
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					UI	Secui	JII 30(II) C	JI LITE	invesiment	CUII	ірапу Асі	01 1940								
1. Name and Address of Reporting Person* FLAUM SANDER A						2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(E	irst)	. _ `										Officer below)	(give title		Other (s below)	pecify			
C/O EAC		3. Date of Earliest Transaction (Month/Day/Year) 01/04/2017																		
(Street) WOODCLIFF LAKE NJ		J	07677			4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Line) X Form filed by One Repor Form filed by More than Person										rting Person				
(City)	(S	tate)	(Zip)																	
		Tab	le I - Nor	ı-Deriv	/ativ	e Se	curities	s Ac	quired, [Disp	osed o	f, or Be	nefici	ally	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/E						ear) i	2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			4 and Securiti Benefic Owned		es Formalially (D) (I) (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	mount (A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
		-	Table II -	Deriva (e.g., p	tive outs,	Secu calls	urities .	Acqı ants	uired, Di , options	spc s, c	sed of, onvertil	or Ben ble secu	eficia urities	ly C)	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)			s. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		expiration vate	Title	Amou or Numb of Share	er						
Stock Option (right to buy)	\$84.92	01/04/2017			A		10,000		(1)	0	1/03/2027	Common Stock	10,00	00	\$0.00	10,000)	D		

Explanation of Responses:

1. The option fully vests on January 4, 2018, subject to the reporting person's continuous service with the issuer as of the vesting date.

Remarks:

/s/ Scott Tarriff, Attorney-in-

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.